SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?


To: nigel bates who wrote (588)4/8/2006 11:59:33 AM
From: nigel bates  Respond to of 590
 
Completion date of 1st April was entirely apt, IMO...

"We continue to believe Amgen retains a high level of confidence of the use of panitumumab (Pmab) in first-line metastatic colorectal cancer to support its estimate of worldwide peak sales of $2 billion (including all indications)..."
siliconinvestor.com

AMGN paid 1x potential peak sales for PMab & the rest for free ?